Engrail Therapeutics

On World Mental Health Day, RiverVest salutes the scientists and health professionals around the world who have dedicated their careers to developing safer, more effective therapeutics for people struggling with mental health disorders. We proudly support Engrail Therapeutics in its efforts to deliver transformational therapies to improve the lives of patients with devastating neuropsychiatric and neurodevelopmental disorders. Last month, Engrail initiated its first-in-human Phase 1 clinical study of ENX-104 for the treatment of major depressive disorder (#MDD) characterized by anhedonia. Recruitment is ongoing for Engrail's Phase 2 clinical study of ENX-102 as a monotherapy treatment in patients with generalized anxiety disorder (#GAD). To learn more about Engrail and its innovative, precision-targeted therapeutics, we invite you to read our recent profile of Vikram Sudarsan, CEO of Engrail, here: https://lnkd.in/grw49GWw #WorldMentalHealthDay #anxiety #depression #anhedonia

Earlier today we announced the initiation of the clinical program for ENX-104, our potent dopamine D2/D3 receptor antagonist in development for major depressive disorder characterized by anhedonia. Dopamine dysregulation in brain reward centers is believed to be an underlying factor in anhedonia. ENX-104 is designed to enhance dopamine neurotransmission by preferential autoreceptor inhibition at low doses. https://lnkd.in/g5ABSKnj We are excited to continue to advance our precision neuroscience pipeline, now with multiple programs in the clinic!

Very excited to advance our next drug into the clinic at Engrail Therapeutics. ENX-104 is a potent D2/D3 receptor antagonist that is designed to address decreased dopamine tone associated with anhedonic depression. The unmet need is very high. Congratulations to our fantastic team on this achievement. Krishna, Kimberly, Estibaliz, Eve - proud of what you and the rest of the team have achieved and grateful to our advisors for excellent input over the past three years supporting our pre-clinical development and clinical development strategies. https://lnkd.in/gzcECA7n

Honored to have attended the 1st International Meeting on Menkes and Other Rare Copper Diseases (MARCO 1) in Málaga. A collaborative environment with top-tier speakers that brought together families, academia, and industry to foster progress and hope. We had a wonderful time connecting with colleagues, friends, and collaborators! #Menkes #RareDiseases #Engrail #CopperDisorders #Collaboration #Innovation #AcademiaAndIndustry #Networking #ScienceForHope #Málaga #Research #Healthcare #PatientSupport #MedicalAdvances

Thank you to Nature Portfolio and Biopharma Dealmakers for the recent coverage of Engrail Therapeutics and how we are de-risking drug development through precision neuroscience. You can download/view the article here: https://lnkd.in/gWPGsw6W

We are excited to announce that Paul Cayer has joined Engrail as Chief Financial Officer. Additionally, Saira Gonsalves Ramasastry has joined the Engrail Board of Directors as Independent Director and Chair of the Audit & Finance Committee. This leadership and governance expansion positions us well to continue advancing our precision neuroscience pipeline. Welcome Paul and Saira! We have also announced a significant additional investment in Engrail by Foresite Capital! With Foresite's investment, we officially closed our Series B round with $167.5M in capital raised.

Our hearts bleed for one our leaders at Engrail. The loss of a child is just unimaginable. Anil, your Engrail family is here for you during this tragic time. Sending much love. ❤️❤️🩹

For those of you attending the Spring MIT Longwood Healthcare Leaders conference June 17 - 18, make sure to listen in on Monday, June 17 at 1 pm ET for a panel discussion on The Future of Mental Healthcare featuring Vikram Sudarsan! https://lnkd.in/exxKDits #neuroscience #engrail #mentalhealth #longwoodhealthcareleaders

We are excited to share that Dr. Estibaliz Arce is participating as a speaker at the upcoming Neuropsychiatric Drug Development Summit. In prelude to this, Esti was featured in an exclusive interview hitting on topics like the evolving psychiatry landscape, the potential for selective GABA-A pharmacology, and the Summit. Bravo Esti!

Let us all remember and honor the sacrifices many individuals made in order for us to live life to the fullest.